PRNewswire (Thu, 6-Aug 11:02 PM ET)
TipRanks (Tue, 4-Aug 1:30 AM ET)
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 30-Jul 6:30 AM ET)
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
Globe Newswire (Tue, 21-Jul 7:00 AM ET)
Market Chameleon (Tue, 7-Jul 7:43 AM ET)
U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease
Globe Newswire (Tue, 7-Jul 7:00 AM ET)
Globe Newswire (Mon, 29-Jun 7:00 AM ET)
Globe Newswire (Sat, 13-Jun 9:00 AM ET)
Globe Newswire (Mon, 1-Jun 5:00 AM ET)
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
Globe Newswire (Fri, 29-May 7:00 AM ET)
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Agios Pharmaceuticals trades on the NASDAQ stock market under the symbol AGIO.
As of August 7, 2026, AGIO stock price climbed to $32.17 with 230,957 million shares trading.
AGIO has a beta of 2.18, meaning it tends to be more sensitive to market movements. AGIO has a correlation of 0.10 to the broad based SPY ETF.
AGIO has a market cap of $1.92 billion. This is considered a Small Cap stock.
Last quarter Agios Pharmaceuticals reported $45 million in Revenue and -$1.69 earnings per share. This beat revenue expectation by $19 million and exceeded earnings estimates by $.02.
In the last 3 years, AGIO traded as high as $62.58 and as low as $19.80.
The top ETF exchange traded funds that AGIO belongs to (by Net Assets): VTI, XBI, VB, IWM, VBK.
AGIO has underperformed the market in the last year with a price return of -14.7% while the SPY ETF gained +23.3%. However, in the short term, AGIO had mixed performance relative to the market. It has outperformed in the last 3 months, returning +19.2% vs +5.6% return in SPY. But in the last 2 weeks, AGIO shares have been beat by the market, returning -11.3% compared to an SPY return of +4.7%.
AGIO support price is $30.82 and resistance is $33.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGIO shares will trade within this expected range on the day.